NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: cyclosporine
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: ifosfamide
Drug: imatinib mesylate
Drug: leucovorin calcium
Drug: mercaptopurine tablet
Drug: methotrexate
Drug: pegaspargase
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Procedure: peripheral blood stem cell transplantation
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 220

Registration Number: NCT00022737

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Phase 2

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Liver Metastases
Stage IV Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IV Colon Cancer

Interventions: Drug: floxuridine
Drug: dexamethasone
Drug: oxaliplatin
Drug: capecitabine

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT00026234

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: medroxyprogesterone
Drug: ethinyl estradiol
Other: laboratory biomarker analysis
Drug: norgestrel

First Posted Date: 2003-01-27

Last Posted Date: 2013-05-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 52

Registration Number: NCT00033358

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Phase 2

Completed

Conditions: Recurrent Uterine Corpus Sarcoma
Uterine Corpus Leiomyosarcoma

Interventions: Drug: Thalidomide
Other: Laboratory Biomarker Analysis

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00025220

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3

Completed

Conditions: Breast Adenocarcinoma
Stage IA Breast Cancer AJCC v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage IIIA Breast Cancer AJCC v7
HER2 Positive Breast Carcinoma
Stage IB Breast Cancer AJCC v7
Stage IIA Breast Cancer AJCC v6 and v7

Interventions: Drug: Aromatase Inhibition Therapy
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Tamoxifen Citrate
Biological: Trastuzumab

First Posted Date: 2003-01-27

Last Posted Date: 2020-08-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3436

Registration Number: NCT00005970

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of Vermont and State Agricultural College, Burlington, Vermont, United States

and more 154 locations

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Epithelial Cancer
Primary Peritoneal Cavity Cancer

Interventions: Drug: bortezomib
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2019-07-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 58

Registration Number: NCT00023712

Locations: 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: gefitinib
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 158

Registration Number: NCT00052208

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Phase 1

Completed

Conditions: Disseminated Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma

Interventions: Drug: R(+)XK469

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 85

Registration Number: NCT00028522

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 1 Follicular Lymphoma